K. Shitara Et Al. , "Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial," JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.11, no.6, 2023
Shitara, K. Et Al. 2023. Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.11, no.6 .
Shitara, K., Di Bartolomeo, M., Mandala, M., Ryu, M., Caglevic, C., Olesinski, T., ... Chung, H. C.(2023). Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial. JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.11, no.6.
Shitara, Kohei Et Al. "Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial," JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.11, no.6, 2023
Shitara, Kohei Et Al. "Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial." JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.11, no.6, 2023
Shitara, K. Et Al. (2023) . "Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial." JOURNAL FOR IMMUNOTHERAPY OF CANCER , vol.11, no.6.
@article{article, author={Kohei Shitara Et Al. }, title={Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial}, journal={JOURNAL FOR IMMUNOTHERAPY OF CANCER}, year=2023}